The Murdoch Childrens Research Institute is participating in a clinical trial testing a new treatment for Fragile X syndrome in adolescents. The treatment is a capsule and the medication is taken twice daily for up to 16 weeks.
To be eligible to participate in the trial, patients must fit the following criteria:
- Be aged 12-17 in otherwise good general health.
- Have a previous diagnosis of Fragile X based on genetic testing (full mutation)
- Have a caregiver who spends on average at least 6 hours a day with the study participant and is willing to supervise treatment, attend all study visits and assist with study assessments
- Have a documented intellectual disability (IQ score less than 70)
The study lasts for a total of 20 weeks and includes a 3-week screening period, 16 weeks during which patients will receive study drug and a one week follow up. All patients will receive a placebo at some stage during the study.
If you would like more details on the trial, please contact Dr Eppie Yiu on 8341 6367, or Ms Geneieve Tai 8341 6374 at the Murdoch Childrens Research Institute.
Comments on this entry are closed.